Lucid Diagnostics, Inc.
(NASDAQ : LUCD)

( )
LUCD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. 0.74%551.361.0%$888.93m
ABMDABIOMED, Inc. 0.08%378.083.3%$745.35m
DHRDanaher Corp. 1.55%267.440.7%$716.34m
MDTMedtronic Plc 0.11%79.110.6%$614.35m
ISRGIntuitive Surgical, Inc. 0.26%265.130.8%$563.08m
ABTAbbott Laboratories 0.93%107.010.8%$532.33m
EWEdwards Lifesciences Corp. 0.63%76.390.4%$499.80m
BDXBecton, Dickinson & Co. 0.35%238.181.0%$430.92m
SYKStryker Corp. 1.16%232.951.3%$392.29m
DXCMDexCom, Inc. -0.82%112.001.9%$331.34m
BSXBoston Scientific Corp. 0.65%44.181.0%$283.04m
BAXBaxter International, Inc. -0.55%55.991.8%$262.67m
ALGNAlign Technology, Inc. -0.82%194.676.4%$255.92m
WSTWest Pharmaceutical Services, Inc. -0.50%226.911.6%$224.33m
AAgilent Technologies, Inc. 0.99%156.881.7%$213.47m

Company Profile

Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.